Lexaria Bioscience (LEXX) Net Cash Flow Growth (3y) (2013 - 2026)
Lexaria Bioscience (LEXX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.63 Mn |
2.11 Mn |
20,000.00 |
38.47% |
| Date | Value |
|---|
| Feb 28, 2026 |
38.47% |
| Nov 30, 2025 |
57.96% |
| Aug 31, 2025 |
-31.27% |
| May 31, 2025 |
-13.53% |
| Feb 28, 2025 |
-4.60% |
| Nov 30, 2024 |
48.58% |
| Aug 31, 2024 |
-38.87% |
| May 31, 2024 |
71.36% |
| Feb 29, 2024 |
-31.91% |
| Nov 30, 2023 |
39.68% |
| Aug 31, 2023 |
-34.65% |
| May 31, 2023 |
-27.80% |
| Feb 28, 2023 |
-25.79% |
| Nov 30, 2022 |
-120.86% |
| Aug 31, 2022 |
-20.32% |
| May 31, 2022 |
-6.04% |
| Feb 28, 2022 |
-70.43% |
| Nov 30, 2021 |
-49.57% |
| Aug 31, 2021 |
119.69% |
| May 31, 2021 |
-69.50% |
